Most Clicked StoriesMore >


BIO report shows low drug-approval success rate

BIO SmartBrief | May 26, 2016

An analysis from BIO involving over 7,400 drug programs found that only 9.6% of drugs that entered clinical trials eventually obtained FDA approval. The report showed that the approval rate for rare disease drugs was 25%, and cancer treatments have the lowest approval rate at 5.1%. The FDA approves 85% of drugs submitted for approval, and it takes 1.6 years on average to gain approval after submission, according to the report. American City Business Journals (05/25)


More firms consider buying Medivation, sources say

BIO SmartBrief | May 26, 2016

Avalon, GSK establish cancer immunotherapy firm

BIO SmartBrief | May 23, 2016

FDA fast-tracks brain aneurysm drug from Edge Therapeutics

BIO SmartBrief | May 23, 2016

XenoPort to be bought by Arbor Pharmaceuticals

BIO SmartBrief | May 24, 2016

Novartis sells 2 hypertension treatments to PDL BioPharma

BIO SmartBrief | May 25, 2016

Hemophilia A drug from CSL Behring approved by FDA

BIO SmartBrief | May 27, 2016

Developer of Humira biosimilar gets $63M in funding

BIO SmartBrief | May 24, 2016

IPO could bring in $75M for immunotherapy developer

BIO SmartBrief | May 25, 2016

Rett syndrome treatment from Anavex gains orphan status from FDA

BIO SmartBrief | May 23, 2016


Find BIO SmartBrief Issues by Date:



BIO News More >


Register for BIO's Executive Training Courses

BIO SmartBrief | May 27, 2016

BIO survey to support PDUFA 6 negotiations

BIO SmartBrief | May 27, 2016

Executive liability coverage for life sciences companies

BIO SmartBrief | May 26, 2016

Savings on environmental waste disposal services

BIO SmartBrief | May 25, 2016

Big savings on lab supplies, equipment & chemicals

BIO SmartBrief | May 24, 2016




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more